Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32. https://doi.org/10.1016/j.annonc.2022.10.003.

Article  CAS  PubMed  Google Scholar 

Benson AB, Venook AP, Adam M, Change G, Chen YJ, Ciombor KK, et al.  Colon cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:e240029. https://doi.org/10.6004/jnccn.2024.0029.

Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377(9779):1749–59. https://doi.org/10.1016/S0140-6736(11)60399-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85. https://doi.org/10.1016/S1470-2045(13)70154-2.

Article  CAS  PubMed  Google Scholar 

Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol. 2018;29(4):835–56. https://doi.org/10.1093/annonc/mdy038.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612–8. https://doi.org/10.1038/s41591-022-01886-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7(10):1529–35. https://doi.org/10.1001/jamaoncol.2021.2915.

Article  PubMed  Google Scholar 

Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388(18):1657–67. https://doi.org/10.1056/NEJMoa2214963.

Article  CAS  PubMed  Google Scholar 

Cervantes A, Martinelli E, clinicalguidelines@esmo.org EGCEa. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Ann Oncol. 2024;35(2):241–3. https://doi.org/10.1016/j.annonc.2023.10.129.

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19. https://doi.org/10.1056/NEJMoa1414325.

Article  PubMed  Google Scholar 

Tabernero J, Argiles G, Sobrero AF, Borg C, Ohtsu A, Mayer RJ, et al. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open. 2020;5(4):e000752. https://doi.org/10.1136/esmoopen-2020-000752.

Article  PubMed  PubMed Central  Google Scholar 

Peeters M, Cervantes A, Moreno Vera S, Taieb J. Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. Future Oncol. 2018;14(16):1629–45. https://doi.org/10.2217/fon-2018-0147.

Article  CAS  PubMed  Google Scholar 

Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843–52. https://doi.org/10.1016/S0140-6736(14)62004-3.

Article  CAS  PubMed  Google Scholar 

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502–8. https://doi.org/10.1200/JCO.2005.10.017.

Article  CAS  PubMed  Google Scholar 

Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33(5):2135–42. https://doi.org/10.3892/or.2015.3876.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017;18(9):1172–81. https://doi.org/10.1016/S1470-2045(17)30425-4.

Article  CAS  PubMed  Google Scholar 

Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412–20. https://doi.org/10.1016/S1470-2045(19)30827-7.

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argiles G, Borg C, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol. 2020;31(9):1160–8. https://doi.org/10.1016/j.annonc.2020.05.024.

Article  PubMed  Google Scholar 

Andre T, Falcone A, Shparyk Y, Moiseenko F, Polo-Marques E, Csoszi T, et al. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol. 2023;8(2):133–44. https://doi.org/10.1016/S2468-1253(22)00334-X.

Article  PubMed  Google Scholar 

Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argiles G, Borg C, et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Br J Cancer. 2022;126(11):1548–54. https://doi.org/10.1038/s41416-022-01737-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andre T, Falcone A, Shparyk YV, Moiseenko FV, Polo E, Csoszi T, et al. Overall survival results for trifluridine/tipiracil plus bevacizumab versus capecitabine plus bevacizumab: results from the phase 3 SOLSTICE study. J Clin Oncol. 2023;41. https://doi.org/10.1200/JCO.2023.41.16_suppl.3512.

Tabernero J, Taieb J, Fakih M, Prager GW, Van Cutsem E, Ciardiello F, et al. Impact of KRAS(G12) mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ESMO Open. 2024;9(3): 102945. https://doi.org/10.1016/j.esmoop.2024.102945.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taieb J, Prager GW, Fakih M, Ciardiello F, van Cutsem E, Elez E, et al. Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: a subgroup analysis of the phase 3 SUNLIGHT trial. J Clin Oncol. 2024;42. https://doi.org/10.1200/JCO.2024.42.3_suppl.111.

Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. Int J Mol Sci. 2018;19(4):1232. https://doi.org/10.3390/ijms19041232.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 2015;67(2):441–61. https://doi.org/10.1124/pr.114.010215.

Article  CAS  PubMed  Google Scholar 

Prager G, Taieb J, Fakih M, Ciardiello F, van Cutsem E, Elez E, et al. Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the phase 3 SUNLIGHT trial. Ann Oncol. 2023;34:S439–40. https://doi.org/10.1016/j.annonc.2023.09.1804.

Article  Google Scholar 

Chebib R, Verlingue L, Cozic N, Faron M, Burtin P, Boige V, et al. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Semin Oncol. 2017;44(2):114–28. https://doi.org/10.1053/j.seminoncol.2017.07.004.

Article  CAS  PubMed  Google Scholar 

Pfeiffer P, Liposits G, Taarpgaard LS. Angiogenesis inhibitors for metastatic colorectal cancer. Transl Cancer Res. 2023;12(12):3241–4. https://doi.org/10.21037/tcr-23-1568.

Article  PubMed  PubMed Central  Google Scholar 

Prager GW, Taieb J, Fakih M, Ciardiello F, van Cutsem E, Elez E, et al. Health-related quality o